Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, USA.
Expert Rev Anti Infect Ther. 2021 Aug;19(8):961-966. doi: 10.1080/14787210.2021.1865801. Epub 2021 Jan 4.
: For those with heavily treatment experienced (HTE) HIV-1 and virologic failure, therapeutic options are limited. A variety of barriers such as drug resistance, side effects, past intolerance, and administration inability contribute to the need for novel drug classes in this population.: Herein, we review the pharmacology, clinical efficacy, and safety profile of fostemsavir, a first in its class attachment inhibitor recently FDA approved for use.: Fostemsavir is a well-tolerated oral medication with relatively few drug-drug interactions. Clinical trial data demonstrates virologic and notable immunologic response in conjunction with optimal background therapy in HTE persons living with HIV. Fostemsavir exhibits no cross-resistance with other ARV classes and thus is an important advancement for patients harboring drug-resistant HIV. Further study will be needed to determine outstanding clinical questions such as the role of drug resistance testing and fostemsavir use outside of the HTE population.
对于那些经历过大量治疗（HTE）且 HIV-1 病毒学失败的患者，治疗选择有限。多种障碍，如耐药性、副作用、过去不耐受和给药困难，导致该人群需要新型药物类别。在此，我们回顾了 fostemsavir 的药理学、临床疗效和安全性，它是一种新型的附着抑制剂，最近被 FDA 批准用于治疗。
Fostemsavir 是一种耐受性良好的口服药物，与其他药物相互作用相对较少。临床试验数据表明，在 HTE 艾滋病毒感染者中，与最佳背景治疗联合使用 fostemsavir 可实现病毒学和显著的免疫反应。Fostemsavir 与其他 ARV 类别没有交叉耐药性，因此对携带耐药性 HIV 的患者是一个重要的进展。需要进一步研究来确定一些尚未解决的临床问题，例如耐药性检测的作用以及在 HTE 人群之外使用 fostemsavir。
